Current price (UNH): $351.81.
Recommended buy zone: $285 or below (accumulate <$300; strong-buy <$285). Rationale: ≤18× 2025 adj. EPS guide of ≥$16 → 18×$16 = ~$288; we want a modest margin of safety given MA utilization risk and ongoing Change/Optum normalization.

UnitedHealth (UNH) — Buffett/Munger-style quick read

• What it does: No.1 U.S. managed-care/payor plus health services (Optum: PBM, clinics, analytics).
• 2025 guide: Revenue $445.5–$448B; adj. EPS ≥$16 (reset year; growth expected to resume in 2026).
• Valuation sanity check: Forward P/E ~20–21× today vs long-run band high-teens/low-20s. Buy when ≤18× this year’s floor EPS; that’s our $285 anchor. (GuruFocus)
• Context/risk: Elevated Medicare Advantage (MA) medical cost trend + lingering Change Healthcare/cyber overhang; management reaffirmed 2025 and expects 2026 re-acceleration.

Checklist — crisp highlights

1) Company: U.S. healthcare plans + services at national scale; diversified across Insurance (UnitedHealthcare) and Optum (Health, Rx, Insight).
2) Quick screen:
• Debt serviceable; mega-cap liquidity. Market cap ~ $315–319B. (Companies Market Cap)
• Scandals/one-offs: 2024–25 Change Healthcare cyberattack costs & remediation. (UnitedHealth Group)
3) Shareholder alignment: Regular disclosures; dividend raised mid-2025; ongoing buybacks. (See 2Q25 release.)
4) Performance: 2Q25 adj. EPS $4.08; 2025 adj. EPS ≥$16 guide (floor).
5) Efficiency: 2025 medical care ratio guided ~89.25% (±25 bps) — watching for normalization as pricing catches up.
6) Financial risk: Investment-grade profile; cyber costs largely recognized; watch MA utilization sensitivity. (The HIPAA Journal)
7) Liquidity/volume: Dow component; ample daily volume. (MarketWatch)
8) Valuation: Today ~20–21× fwd vs ~high-teens historical comfort; prefer ≤18× on guided EPS floor. (GuruFocus)
9) Growth: OptumRx volume, MA membership, and 2026 recovery path post-reset; medium-term depends on pricing catching cost trend.

Straight talk — how I’d trade it

• Discipline: It’s a compounding franchise, but price still matters. I’ll start nibbling <$300 and get greedy <$285. If it stays in the low-300s, I’d wait—we’re paying ~20× a depressed year; I’d rather pay <18× the floor EPS or ~17× if MA costs worsen (≈$272).
• Risk triggers to watch: 1) MA utilization trend plateauing, 2) 2026 EPS trajectory and pricing resets, 3) Optum Health margin rebuild, 4) any residual Change-related liabilities.

New frameworks to think about UNH (beyond ratios)

1. Tri-Engine Flywheel: Underwrite each engine separately.
   • UnitedHealthcare (insurance) = underwriting discipline & rate adequacy.
   • OptumRx (PBM) = script scale + spread resilience.
   • Optum Health = capitation/clinic margins.
     Score each 0/1/2 per quarter; buy only when combined score ≥4 and price ≤18× forward floor EPS.
2. Regulatory Chokepoint Map: Identify where DC rules can compress margins (MA rates, PBM reforms). Assign a % “policy hit” and haircut your EPS floor before setting buy limits. (American Hospital Association)
3. Knife-Edge Margin Test: Stress MCR +50–100 bps. If EPS still covers dividend + buyback capacity and P/E ≤18× on stressed EPS, it’s a green light.
4. Capitation Ladder: Track Optum Health operating margin by cohort maturity (new vs. mature panels). Expand only if mature-cohort margins >5% and climbing.
5. Breach-to-Moat Conversion: Treat Change cyber as a moat test: demand evidence of security spend, vendor hardening, and contract wins attributable to improved posture before re-rating. (UnitedHealth Group)